Akoya Biosciences, Inc. (AKYA)
NASDAQ: AKYA · IEX Real-Time Price · USD
2.850
-0.050 (-1.72%)
At close: May 17, 2024, 4:00 PM
2.900
+0.050 (1.75%)
After-hours: May 17, 2024, 7:29 PM EDT
Akoya Biosciences Revenue
Akoya Biosciences had revenue of $93.57M in the twelve months ending March 31, 2024, with 17.89% growth year-over-year. Revenue in the quarter ending March 31, 2024 was $18.35M, a -14.29% decrease year-over-year. In the year 2023, Akoya Biosciences had annual revenue of $96.63M with 29.09% growth.
Revenue (ttm)
$93.57M
Revenue Growth
+17.89%
P/S Ratio
1.51
Revenue / Employee
$283,555
Employees
330
Market Cap
141.74M USD
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 96.63M | 21.77M | 29.09% |
Dec 31, 2022 | 74.86M | 19.94M | 36.31% |
Dec 31, 2021 | 54.92M | 12.47M | 29.39% |
Dec 31, 2020 | 42.44M | 207.00K | 0.49% |
Dec 31, 2019 | 42.24M | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
TruBridge | 336.45M |
American Well | 254.57M |
So-Young International | 211.29M |
Karyopharm Therapeutics | 140.46M |
InfuSystem Holdings | 127.41M |
OptiNose | 74.02M |
Seer, Inc. | 15.67M |
I-Mab | 3.90M |
AKYA News
- 4 days ago - Akoya Biosciences Reports First Quarter 2024 Financial Results - GlobeNewsWire
- 9 days ago - Akoya Biosciences and NeraCare Enter into an Exclusive Agreement to Enable Personalized Therapy Selection for Early-Stage Melanoma Patients - GlobeNewsWire
- 12 days ago - Akoya Biosciences Opens Operations and Manufacturing Center of Excellence in Marlborough, Massachusetts - GlobeNewsWire
- 16 days ago - Akoya Biosciences and Shanghai KR Pharmtech Announce Chinese Regulatory Agency Premarket Approval for KR-HT5 in China to Support Next Generation Pathology Clinical Workflows - GlobeNewsWire
- 25 days ago - Akoya to Report First Quarter 2024 Financial Results on May 13th, 2024 - GlobeNewsWire
- 6 weeks ago - Akoya Biosciences Showcases Spatial Biology 2.0 Solutions at AACR Annual Meeting with Case Studies Demonstrating Unprecedented Speed and Scale - GlobeNewsWire
- 2 months ago - Akoya Biosciences Names BostonGene as a Qualified CRO Service Provider - Business Wire
- 2 months ago - Akoya Reports Record Revenue in the Fourth Quarter of 2023 and Provides Full Year 2024 Financial Outlook - GlobeNewsWire